Summary
Acute extrapyramidal symptoms (EPS), specifically the motor syndromes of parkinsonism, acute akathisia and acute dystonia, are among the most common adverse effects of antipsychotic medication. They produce physical disability and subjective distress, interfere with psychosocial and occupational adjustment, confound the clinical assessment of psychiatric symptoms, and lead to poor compliance with medication.
Parkinsonism, akathisia and dystonia can also be chronic conditions in patients receiving long term antipsychotic treatment. However, the most common movement disorder seen in such patients is tardive dyskinesia. The presence of the obvious movements of this condition can stigmatise patients. In the more severe cases, disability may be directly related to the particular movements, with interference with mobility, respiration, speech, eating, difficulty swallowing and possibly an increased risk of choking.
To tackle acute EPS, the clinician will need to consider modifying the dosage of conventional antipsychotics or switching to a new antipsychotic that has a lower liability for these problems. If adjunctive drug therapy is considered necessary, the choice will depend partly on the particular extrapyramidal syndrome exhibited by the patient and partly on the adverse effect profiles of the possible treatments.
Anticholinergic (i.e. antimuscarinic) agents are widely used in psychiatric practice to treat and prevent EPS. However, there are hazards with these drugs, including a risk of abuse and toxic confusional states, anticholinergic adverse effects (such as dry mouth, blurred vision, tachycardia, constipation, and urinary hesitation and retention) and cholinergic rebound phenomena on withdrawal. In the light of these problems, it has been recommended that anticholinergic agents are not routinely administered for the prophylaxis of EPS, unless there is a history of acute dystonia or known susceptibility to these antipsychotic-induced motor phenomena. Indeed, the evidence from published studies supports the value of anticholinergic drugs as treatment for EPS rather than for prophylaxis.
Despite the efficacy of anticholinergic drugs, not all EPS are equally responsive to this treatment. The tremor and rigidity of parkinsonism are reliably relieved by these agents. However, this syndrome is known to abate spontaneously over time. After 3 months, the majority of patients initially requiring treatment with anticholinergics can have this therapy withdrawn without a relapse of parkinsonian symptoms. Therefore, anticholinergics should be periodically withdrawn to test the need for their continued prescription.
Acute dystonic reactions are also effectively treated with anticholinergic drugs. In severe cases, intravenous or intramuscular administration can provide relief in minutes. The place of anticholinergics in the treatment of tardive dystonia is less clear, as only a proportion of patients will show any benefit.
Anticholinergics also have an uncertain reputation in both acute and chronic akathisia, being of limited efficacy. Acute akathisia may respond best to anticholinergics if it is accompanied by parkinsonism, in which case both syndromes may improve.
Anticholinergic drugs are not effective in alleviating tardive dyskinesia. The evidence suggests that these agents can sometimes worsen the movements, and when discontinued, a modest improvement may be seen in a proportion of patients exhibiting this condition. However, it has not been established that patients receiving antiparkinsonian medication in addition to antipsychotic medication are at a greater risk of developing tardive dyskinesia.
Similar content being viewed by others
References
Barnes TRE. Movement disorder associated with antipsychotic drugs: the tardive syndromes. Int Rev Psychiatry 1990; 2: 355–66
Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15Suppl. 1: S57–63
Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989; 12: 148–51
Eglen RM, Reddy H, Watson N. Selective inactivation in muscarinic receptor subtypes. Int J Biochemistry 1994; 26 (12): 1357–68
Tune L, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460–2
Modell JG, Tandon R, Beresford TP. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol 1989; 9: 347–51
Chouinard G, Annable L, Ross-Chouinard A, et al. A five year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8: 21S–6S
Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand 1988; 77: 369–78
Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Psychopharmacologia 1975; 43: 103–13
Crow TJ, Frith CD, Johnson EC, et al. The influence of anticholinergic medication on the extrapyramidal and anti-psychotic effects of neuroleptic drugs in the treatment of acute schizophrenia. Biol Psychiatry 1981; 16: 790–2
Johnstone E, Crow T, Ferrier N, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513–27
Woody GE, O’Brien CP. Anticholinergic toxic psychosis in drug abusers treated with benztropine. Compr Psychiatry 1974; 15: 439–42
Mac Vicar K. Abuse of antiparkinson drugs by psychiatric patients. Am J Psychiatry 1977; 134: 809–11
Smith JM. Abuse of the antiparkinson drugs: a review of the literature. J Clin Psychiatry 1980; 41: 351–4
Crawshaw JA, Mullen PE. A study of benzhexol abuse. Br J Psychiatry 1984; 145: 300–3
Aguilera L, Martinez-Bourio R, Cid C, et al. Anaphylactic reaction after atropine. Anaesthesia 1988; 43: 955–7
Gardos G, Cole JO, Tarsy D. Withdrawal syndrome associated with antipsychotic drugs. Am J Psychiatry 1978; 135: 1321–4
Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. Arch Gen Psychiatry 1981; 35: 483–9
Chouinard G, Bradwejn J, Annable L, et al. Withdrawal symptoms after long-term treatment with low-potency neuroleptic drugs. J Clin Psychiatry 1984; 45: 500–2
George V, Castot A, Bidault I. Existe-t-il un syndrome de sevrage specifique aux antiparkinsoniens dopaminergiques? Therapie 1987; 42: 339–41
Bermanzohn PC, Siris SG. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon. J Clin Psychiatry 1994; 55: 488–91
Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977; 27(8); 783–90
Kopelman MD, Corn TH. Cholinergic ‘blockade’ as a model for cholinergic depletion: a comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakov syndrome. Brain 1988; 111Ft 5: 1079–110
Hitri A, Craft RB, Fallon J, et al. Serum neuroleptic and anticholinergic activity in relation to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol Bull 1987; 23: 33–7
Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983; 143: 584–90
Pullen GP, Best NR, MacGuire J. Anticholinergic drug abuse: a common problem? BMJ 1984; 289: 612–3
Wells BG, Marken PA, Rickman LA, et al. Characterizing anticholinergic abuse in the community. J Clin Psychopharmacol 1989; 9: 431–5
Leipzig RA, Mendelowitz A. Adverse psychotropic drug-drug interactions. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: The Guilford Press, 1992: 13–76
Tonda ME, Guthrie SK. Treatment of neuroleptic-induced movement disorders. Pharmacotherapy 1994; 14: 543–60
Leon JD, Simpson GM. Assessment of neuroleptic-induced extrapyramidal symptoms. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: The Guilford Press, 1992: 218–34
Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 9: 538–44
Lavin MR, Rifkin A. Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of side effects. J Clin Pharmacol 1991; 31: 763–8
Ebel H. Therapy of neuroleptic-induced extrapyramidal movement disorders. Neurol Psychiatry Brain Res 1994; 2: 140–51
Lake CR, Casey DE, McEvoy JP, et al. The ‘pros’ and ‘cons’ of anticholinergic prophylaxis. Psychopharmacol Bull 1986; 22: 981–4
Winslow RS, Stiller V, Coons DJ, et al. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. Am J Psychiatry 1986; 143: 706–10
Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol 1987; 7: 164–6
Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987; 7: 342–5
Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988; 145: 993–6
Goff DC, Arana GW, Greenblatt DJ, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991; 11: 106–12
Manos N, Lavrentiadis G, Ckiouzepas J. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. J Clin Psychiatry 1986; 47: 114–6
Rifkin A, Quitkin F, Kane JM, et al. Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 1978; 35: 483–9
World Health Organization, Heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990; 156: 412
McClelland HA, Blessed G, Bhate S, et al. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. Br J Psychiatry 1974; 124: 151–9
Orlov P, Kasparian G, Dimascio A, et al. Withdrawal of antiparkinson drugs. Arch Gen Psychiatry 1971; 25: 410–2
Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 1970; 212: 11–9
Raleigh FR. Reducing unnecessary antiparkinson medication in antipsychotic drug therapy. J Am Pharm Assoc 1977; NS17: 101–2
Johnson DAW. Prevalence and treatment of drug-induced extrapyramidal symptoms. Br J Psychiatry 1978; 132: 27–30
Silver H, Geraisy N, Schwartz M. No differences in the effect of biperiden and amantadine on parkinsonian and tardive dyskinesia-type involuntary movements: a double-blind crossover placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995; 56: 167–70
Mindham RHS. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. Br J Clin Pharmacol 1976; Suppl.: 395–400
Comaty JE, Janicak MD, Rajaratnam J, et al. Is maintenance antiparkinsonian treatment necessary? Psychopharmacol Bull 1990; 26: 267–70
Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinson medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry 1981; 138: 184–8
Klett CJ, Point P, Caffey E. Evaluating the long-term need for antiparkinsonian drugs by chronic schizophrenics. Arch Gen Psychiatry 1972; 26: 375–9
Leegood H, Barnes TRE, Liddle PF. The effects of abrupt procyclidine withdrawal in a chronic schizophrenic inpatient population - a double-blind study [abstract]. Psychiatr Bull 1991; 15 Suppl. 4: 92
Barnes TRE. Comment on the WHO consensus statement. Br J Psychiatry 1990; 156: 413–4
Van Putten T, May PRA. ‘Akinetic depression’ in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101–7
Barnes TRE, McPhillips MA. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol 1995; 10Suppl. 3: 115–21
Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993; 163Suppl. 22: 66–78
Hogarty GE, McEvoy JP, Ulrich RF, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52: 29–41
Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate and low-dose regimens. J Clin Psychiatry 1986; 47 Suppl.: 30–4
Swett CJ. Drug-induced dystonia. Am J Psychiatry 1975; 132: 532–4
Burke RE. Neuromuscular effects of neuroleptics: dystonia. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992: 189–200
Angus JWS, Simpson GM. Hysteria and drug-induced dystonia. Acta Psychiatr Scand 1970; 212: 52–8
Rupniak NMJ, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 103: 138–9
Addonzio G, Alexopolous GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988; 145: 869–71
Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60
Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology 1979; 61: 261–2
British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 31. London: British Medical Association and The Pharmaceutical Press, 1996 Mar
Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–46
Sachdev P. Risk factors for tardive dystonia: a case control comparison with tardive dyskinesia. Acta Psychiatr Scand 1993; 88: 98–103
Friedman JH, Kuraski LT, Wagner RI. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987; 50: 801–3
Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986; 73: 629–33
Marsden CD, Quinn NP. The dystonias. BMJ 1990; 300: 139–44
Jankovic J, Schwartz K. Botulinum toxin injection for cervical dystonia. Neurology 1990; 40: 277–80
Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 1992; 85: 525–9
Safferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17: 247–61
Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia. Mov Disord 1994; 9: 321–4
Barnes TRE. Neuromuscular effects of neuroleptics: akathisia. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992: 201–17
Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983; 143: 139–50
Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994; 51: 963–74
Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67–72
Van Putten T, Marder S. Behavioural toxicity of antipsychotic drugs. J Clin Psychiatry 1987; 48: 13–9
Ayd FJ. Akathisia and suicide: fact or myth? Int Drug Ther News Lett 1988; 23: 37–8
Wilbur R, Kulik AV. Propranolol for akathisia [letter]. Lancet 1983; II: 917
Lipinski JF, Zubenko GS, Cohen BN, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1983; 141: 412–5
Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149: 42–5
Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. Acta Psychiatr Scand 1983; 67: 178–87
Kruse W. Persistent muscular restlessness after phenothiazine treatment: a report of three cases. Am J Psychiatry 1960; 17: 152–3
Marsden CD, Tarsy D, Baldessarini RJ. Spontaneous and drug-induced movement disorders in psychiatric patients. In: Benson DF, Blumer D, editors. Psychiatric aspects of neurological disease. New York Grune and Stratton, 1975: 219–65
Sovner R, DiMascío A. Extrapyramidal syndromes and other neurological side-effects of psychotropic drugs. In: Lipton MA, Di Mascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven Press, 1978: 1021–32
Weiner WJ, Luby ED. Persistent akathisia following neuroleptic withdrawal. Ann Neurol 1983; 13: 466–7
Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–8
Gibb WRG, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 1986; 49: 861–6
Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors 1959-1979. Arch Gen Psychiatry 1982; 39: 473–81
Wada Y, Yamaguchi N. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients. Neuropsychobiology 1992; 25: 149–52
Yassa R, Lai S. Prevalence of the rabbit syndrome. Am J Psychiatry 1986; 143: 656–7
Gardos G, Cole JO. Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 1983; 140: 200–2
Kane JM, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254–8
Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6
Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barnes, T.R.E., McPhillips, M.A. Antipsychotic-Induced Extrapyramidal Symptoms. CNS Drugs 6, 315–330 (1996). https://doi.org/10.2165/00023210-199606040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199606040-00006